Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 14/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31237545 | 0.91 | ALOX5 (0.86) | ALOX5PTGS2 | |
| SCHEMBL68698 | 0.87 | ALOX5 (0.77) | ALOX5PTGS2CYP3A4MAPT | |
| SCHEMBL22410475 | 0.85 | ALOX5 (0.73) | ALOX5PTGS2CYP3A4HTR2AMEN1 | |
| SCHEMBL18987306 | 0.85 | ALOX5 (0.73) | ALOX5PTGS2HTR2ATDP1 | |
| SCHEMBL15758094 | 0.83 | ALOX5 (0.71) | ALOX5PTGS2HTR2AMAPTTSHR | |
| SCHEMBL15151834 | 0.83 | ALOX5 (0.74) | ALOX5PTGS2CYP3A4HTR2AMEN1 | |
| SCHEMBL15151837 | 0.83 | ALOX5 (0.74) | ALOX5PTGS2CYP3A4HTR2AMEN1 | |
| SCHEMBL21558842 | 0.83 | ALOX5 (0.74) | ALOX5PTGS2HTR2A | |
| SCHEMBL18342948 | 0.83 | ALOX5 (0.74) | ALOX5PTGS2HTR2A | |
| SCHEMBL29711563 | 0.83 | ALOX5 (0.74) | ALOX5PTGS2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080254130-A1 | Skin Antiaging & Brightening via Multi-function Treatment of Enzyme Dysfunction | BIODERM RESEARCH (US) | 2008-10-16 | — | — | US | disclosed |
| US-20050271608-A1 | Skin whitening compositions based on hydroxyaryl alkyl ketones and their isosteric derivatives | GUPTA SHYAM K | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080254130-A1 | Skin Antiaging & Brightening via Multi-function Treatment of Enzyme Dysfunction | PSMB1, PLOD3, CUTA | ALOX5 491/4885PTGS2 1014/4885CYP3A4 3624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.